日本語 EN 中文

由前沿细胞设计技术塑造的医疗未来

细胞设计医学研究所(RICeD)旨在成为国际化的研发中心,通过创新的细胞设计技术——山口大学的核心优势,不断培育出下一代细胞和基因疗法的创新成果。
RICeD还致力于推动基于创新技术的前沿免疫疗法和基因组医学的实际应用,开发用于癌症和遗传病等疑难疾病的治疗方法,并在伴侣动物中应用和验证这些创新疗法。
通过在人类和伴侣动物之间建立知识互通的积极循环,RICeD将努力通过技术的社会应用形成药物发现生态系统,推动地方社区发展,通过产业创造培养人才,并延长人类和伴侣动物的健康寿命。

  • ALL
  • News
  • Thesis
  • Recruiting
*Announcement* Phase I/IIa Clinical Trial of Human (Allogeneic) Subcutaneous Adipose Tissue-Derived Mesenchymal Stem Cell Sheet (PAL-222) Transplantation in Neovascular Age-Related Macular Degeneration Refractory to Existing Treatments (Trial Title: PRESERVE Study)

News

2025.04.23

*Announcement* Phase I/IIa Clinical Trial of Human (Allogeneic) Subcutaneous Adipose Tissue-Derived Mesenchymal Stem Cell Sheet (PAL-222) Transplantation in Neovascular Age-Related Macular Degeneration Refractory to Existing Treatments (Trial Title: PRESERVE Study)

Pilot study of autologous multilayered fibroblast sheet transplantation for reinforcing bronchial stump healing after pulmonary lobectomy in a canine model

Thesis

2025.04.17

Pilot study of autologous multilayered fibroblast sheet transplantation for reinforcing bronchial stump healing after pulmonary lobectomy in a canine model

*Announcement* Crowdfunding Goal Reached

News

2025.04.04

*Announcement* Crowdfunding Goal Reached

*Report* Open Seminar of the Division of Advanced Genome Editing Therapy was held.

News

2025.03.28

*Report* Open Seminar of the Division of Advanced Genome Editing Therapy was held.

Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential

Thesis

2025.03.03

Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential

*Announcement* Presentation at the Lunch Meeting of the Research Institute and Center Conference

News

2025.02.26

*Announcement* Presentation at the Lunch Meeting of the Research Institute and Center Conference

*Notice* Currently exhibiting at the Osaka-Kansai Expo pre-event!

News

2025.02.13

*Notice* Currently exhibiting at the Osaka-Kansai Expo pre-event!

*Notice* UBE Corporation and UBE Corporation Commence Joint Research on Novel Combination Cancer Immunotherapy

News

2025.02.07

*Notice* UBE Corporation and UBE Corporation Commence Joint Research on Novel Combination Cancer Immunotherapy

Read More

RICeD捐款请求

我们正在推进尖端癌症免疫疗法的开发,以治愈更多患者。
我们还致力于将全球首创的基因编辑技术应用于伴侣动物的遗传病治疗,并将研究成果进一步应用于人类医学,以延长人类和伴侣动物的健康寿命。为实现这些目标,并持续推动研究成果的社会应用,我们真诚地请求您的支持。

点击此处捐款

Instagram

ー Follow us! ー